Epigenetics in NAFLD/NASH: Targets and therapy

Sodum, Nalini and Kumar, Gautam and Bojja, Sree Lalitha and Kumar, Nitesh and Rao, Mallikarjuna C (2021) Epigenetics in NAFLD/NASH: Targets and therapy. Pharmacological Research, 167 (80). pp. 1-16. ISSN 1043-6618

[img] PDF
RMS - 00014824.pdf - Published Version
Restricted to Registered users only

Download (9MB) | Request a copy


Recently non-alcoholic fatty liver disease (NAFLD) has grabbed considerable scientific attention, owing to its rapid increase in prevalence worldwide and growing burden on end-stage liver diseases. Metabolic syndrome including obesity, diabetes, and hypertension poses a grave risk to NAFLD etiology and progression. With no drugs available, the mainstay of NAFLD management remains lifestyle changes with exercise and dietary modifications. Nonselective drugs such as metformin, thiazolidinediones (TZDs), ursodeoxycholic acid (UDCA), silymarin, etc., are also being used to target the interrelated pathways for treating NAFLD. Considering the enormous disease burden and the unmet need for drugs, fresh insights into pathogenesis and drug discovery are required. The emergence of the field of epigenetics offers a convincing explanation for the basis of lifestyle, environmental, and other risk factors to influence NAFLD pathogenesis. Therefore, understanding these epigenetic modifications to target the primary cause of the disease might prove a rational strategy to prevent the disease and develop novel therapeutic interventions. Apart from describing the role of epigenetics in the pathogenesis of NAFLD as in other reviews, this review additionally provides an elaborate discussion on exploiting the high plasticity of epigenetic modifications in response to environmental cues, for developing novel therapeutics for NAFLD. Besides, this extensive review provides evidence for epigenetic mechanisms utilized by several potential drugs for NAFLD.

Item Type: Article
Uncontrolled Keywords: 3-deazaneplanocin A (PubChem CID: 73087); Berberine (PubChem CID: 2353); DNA methylation; Ezetimibe (PubChem CID: 150311); Gemfibrozil (PubChem CID: 3463); HDAC; Histone modification; Liraglutide (PubChem CID: 16134956); Metformin (PubChem CID: 4091); MicroRNAs; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Resveratrol (PubChem CID: 445154); Rimonabant hydrochloride (PubChem CID: 104849); Sitagliptin (PubChem CID: 4369359); Vitamin E (PubChem CID: 14985); Vorinostat (PubChem CID: 5311); β-cryptoxanthin (PubChem CID: 5281235).
Subjects: Pharmacy > MCOPS Manipal > Pharmacology
Depositing User: KMC Library
Date Deposited: 29 Mar 2022 11:36
Last Modified: 29 Mar 2022 11:36
URI: http://eprints.manipal.edu/id/eprint/158505

Actions (login required)

View Item View Item